For instance, SRT1720 has been demonstrated to extend lifespan and improve metabolic syndrome, insulin sensitivity, and endothelial dysfunction in mice, while a related compound, SRT2104, has undergone clinical phase I and II trials, revealing only minor adverse effects (112). The gene discussed is INS; the disease is metabolic syndrome.